CYTK CYTOKINETICS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1061983 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY29.9%
TTM net income YoY-3.5%
TTM EPS YoY4.4%
Revenue 3-yr CAGR143.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-625.2%
Net margin-686.6%
FCF margin-519.5%
EBITDA margin-613.2%
Returns
ROE—
ROA-47.7%
ROIC (approx.)—
Asset turnover0.07x
Leverage & solvency
Liabilities / assets117.6%
Debt / equity—
Current ratio3.36x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue14.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $88.04M | $18.47M | $7.53M | $94.59M | $70.43M |
| R&D expense | $416.03M | $339.41M | $330.12M | $240.81M | $159.94M |
| SG&A expense | $284.27M | $215.31M | $173.61M | $177.98M | $96.80M |
| Operating income | -$612.26M | -$536.25M | -$496.20M | -$324.20M | -$186.31M |
| Interest expense | $45.58M | $37.70M | $28.31M | $19.41M | $16.44M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$784.96M | -$589.53M | -$526.24M | -$388.95M | -$215.31M |
| EBITDA | -$602.13M | -$526.72M | -$484.31M | -$318.39M | -$184.04M |
| EPS (basic) | -6.54 | -5.26 | -5.45 | -4.33 | -2.80 |
| EPS (diluted) | -6.54 | -5.26 | -5.45 | -4.33 | -2.80 |
| Weighted avg. shares (diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 |
| Balance sheet | |||||
| Cash & equivalents | $122.52M | $94.86M | $113.02M | $65.58M | $112.67M |
| Short-term investments | $759.70M | $981.16M | $501.80M | $717.00M | $358.97M |
| Receivables | $17.76M | $16.65M | $1.28M | $147,000 | $51.82M |
| Inventory | $0 | — | — | — | — |
| Current assets | $916.98M | $1.11B | $628.05M | $795.19M | $535.67M |
| PP&E, net | $79.19M | $65.81M | $68.75M | $80.45M | $73.27M |
| Total assets | $1.42B | $1.40B | $824.32M | $1.01B | $841.32M |
| Current liabilities | $202.45M | $179.67M | $102.68M | $84.62M | $71.86M |
| Short-term debt | $41.18M | $11.52M | $10.08M | $958,000 | — |
| Long-term debt | $246.38M | $93.23M | $58.38M | $63.81M | $47.37M |
| Total debt | $287.56M | $104.75M | $68.46M | $64.77M | $47.37M |
| Total liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597.46M |
| Shareholders' equity | -$659.62M | -$135.37M | -$386.32M | -$107.90M | $243.86M |
| Net debt | $165.05M | $9.89M | -$44.56M | -$814,000 | -$65.30M |
| Shares outstanding | 122.94M | 118.21M | 101.64M | 94.83M | 84.80M |
| Cash flow statement | |||||
| Operating cash flow | -$510.01M | -$395.89M | -$414.33M | -$299.52M | -$142.52M |
| Capital expenditure | $24.81M | $3.91M | $1.42M | $11.34M | $48.87M |
| Free cash flow | -$534.82M | -$399.80M | -$415.75M | -$310.85M | -$191.39M |
| Investing cash flow | $16.67M | -$553.10M | $239.25M | -$262.13M | -$147.78M |
| Financing cash flow | $524.46M | $930.61M | $221.32M | $516.17M | $319.98M |
| Depreciation & amortization | $10.12M | $9.53M | $11.89M | $5.81M | $2.28M |
| Stock-based compensation | $112.29M | $97.84M | $72.06M | $47.85M | $26.83M |
Free plan shows the latest 5 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.